Amplia Therapeutics Limited (ATX.AX)
Amplia Therapeutics Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $0.14, up 0.00% on the session, giving a market capitalisation of $71.9M. Its beta of -0.40 implies it has historically moved less than the broad market.
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Amplia Therapeutics Limited is most often compared with the following Healthcare names: